Terminalia arjuna is promoted as a heart-health supplement, and lowering cholesterol is one of the claims attached to it. Unlike many herbal cholesterol products, Arjuna has been tested in people, including a randomized controlled trial that measured LDL cholesterol directly.
Human studies have reported reductions in LDL, but they do not establish how reliably modern Arjuna supplements reproduce those effects or whether taking Arjuna reduces cardiovascular events.
Key Takeaways
- A small randomized controlled trial found that Terminalia arjuna bark powder reduced LDL cholesterol over 30 days.
- Other studies have reported improvements in cholesterol when Arjuna was added to conventional cardiovascular treatment.
- Bark powder and different extracts are not necessarily interchangeable, and an established dose for lowering LDL has not been determined.
- Laboratory research offers several possible explanations for its lipid effects, but these mechanisms do not prove how well a supplement will work in people.
- Long-term safety, drug interactions and effects on cardiovascular events remain uncertain.
What Is Terminalia Arjuna?
Terminalia arjuna, commonly called Arjuna, is a tree native to the Indian subcontinent. Its stem bark has a long history of use in Ayurvedic medicine, particularly for cardiovascular conditions. Modern research has consequently focused heavily on the bark rather than other parts of the plant.
What Did the 30-Day Cholesterol Trial Find?
One of the more useful human studies involved 105 people with coronary heart disease. They were divided into three groups of 35. One group received placebo capsules, another received 400 IU of vitamin E per day, and the third received 500 mg of finely powdered Terminalia arjuna bark per day.
After 30 days, the Arjuna group had an average 15.8% reduction in LDL cholesterol and a 9.7% reduction in total cholesterol. Significant changes in these cholesterol measures were not observed in the placebo or vitamin E groups. Lipid peroxide levels also fell in both the Arjuna and vitamin E groups.
Only 35 participants received Arjuna, and the reported LDL reduction was 15.8 ± 25.6%, indicating considerable variation within the group. The trial lasted only one month and involved people who already had coronary heart disease. It does not establish what would happen over six months or several years, or whether the same response would occur in otherwise healthy people with elevated LDL.
What Did Other Human Studies Find?
A separate report summarized in the reviews involved 30 people with coronary artery disease who received Arjuna bark powder alongside conventional treatment, including statin therapy. After three months, LDL cholesterol reportedly fell by 16%, total cholesterol by 15%, and triglycerides by 11%.
Those numbers cannot be attributed to Arjuna alone because the participants were also receiving conventional treatment.
Another placebo-controlled, double-blind study involved 100 people with stable coronary artery disease. Participants received conventional treatment, with one group also taking 500 mg of T. arjuna twice daily. The review reports improvements in hyperlipidaemia and reductions in several inflammatory markers after three months.
The studies used different treatment regimens and durations, and some tested Arjuna only as an addition to existing cardiovascular therapy.
How Could Terminalia Arjuna Affect Cholesterol?
Laboratory experiments with aqueous and alcoholic Arjuna bark extracts found inhibition of HMG-CoA reductase, an enzyme involved in cholesterol synthesis. Experimental research has also suggested increased clearance of cholesterol by the liver and reduced activity of enzymes involved in lipid production.
Arjuna bark also contains polyphenols, flavonoids and other compounds with antioxidant activity. Experimental studies suggest these compounds can reduce lipid oxidation and oxidative stress.
Most of this mechanistic evidence comes from laboratory or animal experiments. Inhibiting an enzyme in a cell model does not tell us how much LDL a person taking an Arjuna supplement will lose.
Reducing LDL oxidation is also different from reducing the amount of LDL circulating in the blood. The 30-day human trial is more informative for that question because it measured serum LDL directly.
Is There an Established Arjuna Dose for Lowering LDL?
No standardized dose for lowering LDL has been established from these studies.
The strongest controlled cholesterol study used 500 mg of powdered bark once daily, while other cardiovascular studies have used 500 mg two or three times daily or different types of extracts.
Those amounts are study protocols rather than established dosing recommendations.
Does the Type of Arjuna Supplement Matter?
Potentially, yes.
The chemical composition of an Arjuna preparation depends partly on how it is produced. Research reviewed by Ramesh and Palaniappan shows that water, ethanol, methanol and other solvents extract different groups and amounts of phytochemicals from the plant material.
The 30-day cholesterol trial used finely pulverized tree-bark powder, not an arbitrary standardized extract. A modern capsule labelled “500 mg Terminalia arjuna extract” therefore cannot be assumed to reproduce the dose or chemical exposure from that study.
Reviews of the evidence have identified lack of phytochemical standardization and limited bioavailability data as shortcomings of the research.
Can You Take Terminalia Arjuna With Statins?
Arjuna has been used alongside statins in clinical research, but that does not establish that every Arjuna product can be safely combined with every statin.
Alcoholic and aqueous Arjuna bark extracts inhibited CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. These enzymes are involved in the metabolism of many medications. The inhibition was observed in laboratory experiments, so it does not prove that clinically important interactions occur at normal supplement doses.
The 2014 review specifically identified interactions with statins, aspirin, ACE inhibitors and beta blockers as areas where better studies were needed.
Someone already taking cholesterol-lowering or cardiovascular medication should therefore not interpret the small add-on studies as proof that combining the treatments is safe.
What Side Effects Have Been Reported?
The clinical literature reviewed by Dwivedi and Chopra included reports of mild adverse effects such as nausea, gastritis, headache, body aches, constipation and insomnia. The review did not identify hematological, renal or metabolic toxicity in the longer studies it examined.
There are also animal findings involving changes in thyroid hormones and possible liver toxicity at high exposures. Those findings do not establish the same risk in humans taking ordinary supplement doses.
Long-term toxicity, bioavailability, standardized composition and drug interactions remain inadequately studied.
How Strong Is the Evidence?
Arjuna has direct human cholesterol evidence rather than a claim based entirely on test-tube or animal experiments. The 105-person trial is particularly relevant because it included placebo and vitamin E comparison groups and measured LDL directly.
Its Arjuna arm was small and short-term, while much of the broader clinical literature involves people with established coronary disease. Some studies also added Arjuna to conventional medication rather than testing it independently.
Different preparations further complicate comparison between trials and make it difficult to identify a formulation that should reliably reproduce the reported LDL effects.
Most importantly, the research reviewed here primarily measures surrogate outcomes, such as LDL cholesterol, lipid oxidation and inflammatory markers. It does not establish that taking Arjuna reduces heart attacks, strokes or cardiovascular mortality. The 2014 review specifically identified its role in primary and secondary coronary prevention as unresolved.
Can Terminalia Arjuna Replace a Statin?
No evidence reviewed here establishes Arjuna as a replacement for statin therapy.
As discussed above, the available studies do not demonstrate equivalent protection against cardiovascular events. Some of the research also tested Arjuna in addition to conventional cardiovascular treatment, so those studies cannot support removing that treatment and substituting Arjuna.
Bottom Line
Terminalia arjuna has a genuine signal for LDL lowering. A randomized controlled trial reported a reduction in LDL after one month of Arjuna bark powder, and other clinical studies have reported improvements in lipid measures.
How reproducible that effect is remains unclear. The clinical evidence is small, the preparations differ, long-term data are sparse, and there is no established formulation or dose that can be expected to lower LDL by a particular amount.
The current evidence supports further study of Arjuna for cholesterol lowering, but not its use as a proven alternative to established lipid-lowering treatment.
FAQs
How Quickly Can Terminalia Arjuna Lower Cholesterol?
The main controlled cholesterol trial measured significant changes after 30 days. That tells us when the researchers measured an effect, not that Arjuna reliably begins lowering LDL within a specific number of days.
Does Terminalia Arjuna Lower Triglycerides?
Some human research has reported lower triglycerides, including a study in which Arjuna was used with conventional cardiovascular treatment. Because other treatment was being used at the same time, the independent effect of Arjuna on triglycerides is unclear.
Does Terminalia Arjuna Increase HDL?
The strongest 30-day study produced significant reductions in total and LDL cholesterol, but it did not establish a similarly clear HDL-raising effect. Claims that Arjuna reliably increases HDL are therefore less well supported than the LDL claim.
Is Arjuna Bark Powder the Same as Terminalia Arjuna Extract?
No. Bark powder is the ground plant material, while extracts are produced using solvents such as water or alcohol. Extraction method can change the chemical composition of the resulting preparation.
Is 500 mg of Terminalia Arjuna an Effective Dose?
Several human studies used 500 mg preparations, but the products and dosing schedules differed. The research does not establish 500 mg as a universal effective dose.
References
Amalraj, A., & Gopi, S. (2017). Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A review. Journal of Traditional and Complementary Medicine, 7(1), 65–78. https://doi.org/10.1016/j.jtcme.2016.02.003
Dwivedi, S., & Chopra, D. (2014). Revisiting Terminalia arjuna: An ancient cardiovascular drug. Journal of Traditional and Complementary Medicine, 4(4), 224–231. https://doi.org/10.4103/2225-4110.139103
Rajaram, V., Namasivayam, A., Shanmugam, R., Mahendra, J., Sudhakar, U., Munusamy, T., & Subbiah, U. (2024). Terminalia arjuna: An overview of its magical properties. Bioinformation, 20(12), 2080–2085. https://doi.org/10.6026/9732063002002080
Ramesh, P., & Palaniappan, A. (2023). Terminalia arjuna, a cardioprotective herbal medicine: Relevancy in the modern era of pharmaceuticals and green nanomedicine: A review. Pharmaceuticals, 16(1), 126. https://doi.org/10.3390/ph16010126
Leave a Reply